Lumos Diagnostics Holdings Limited

Equities

LDX

AU0000157091

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
0.061 AUD 0.00% Intraday chart for Lumos Diagnostics Holdings Limited -7.58% -16.44%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lumos Diagnostics Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Lumos Diagnostics Hires Henry Schein as US Distributor for Respiratory Infection Blood Test; Shares Rise 4% MT
Lumos Diagnostics' Q4 Revenue Jumps 55% MT
Australian Shares Rise Ahead of US Inflation Data MT
Lumos Diagnostics Signs Development and IP Agreements with Hologic; Shares Up 24% MT
Lumos Signs Major Development and IP Agreements with Hologic, Inc CI
Lumos Diagnostics Raises AU$2.7 Million to Support US Launch of FebriDx, ViraDx; Shares Down 6% MT
US FDA Grants Emergency Use Authorization for Lumos Diagnostics' ViraDx MT
Lumos Diagnostics Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Lumos Diagnostics Secures Europe, Japan Patents for Core Camera Reader MT
Lumos Diagnostics Expands FebriDx Market to Netherlands MT
Lumos Diagnostics Announces Core Camera Reader Patent Granted in Europe and Japan CI
Lumos Diagnostics Secures R&D Tax Rebate for Fiscal Year 2022 MT
Lumos Diagnostics Signs Partnership with Henry Schein Medical for FebriDx Distribution; Shares Jump 8% MT
Lumos Diagnostics Holdings Limited Appoints Doug Ward to Board as Managing Director CI
Lumos Diagnostics Secures US FDA Clearance for Bacterial Respiratory Infection Test MT
Lumos Diagnostics Secures AU$9 Million in Funding from New Agreements With US Healthcare Company MT
Lumos Diagnostics Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Lumos Diagnostics Wins Two Service Agreements from Health Company Hologic MT
Lumos Diagnostics Secures Two Service Agreements with Hologic CI
Lumos Diagnostics Holdings Limited announced that it expects to receive AUD 8 million in funding from SBC Global Investors, The Lind Partners, LLC CI
Lumos Diagnostics Reports Higher Revenue in Fiscal Q1 MT
Lumos Diagnostics Announces Publication of Data from DISRUPT Clinical Trial of FebriDx in JAMA Open Network CI
US FDA Rejects Lumos Diagnostics' Respiratory Diagnostic Test Following Appeal MT
Lumos Diagnostics Closes Sarasota Facility, Relocates Manufacturing Unit to California's Carlsbad MT
Chart Lumos Diagnostics Holdings Limited
More charts
Lumos Diagnostics Holdings Ltd is an Australia-based company, which specializes in point-of-care (POC) diagnostic test technology to help healthcare professionals diagnose and manage medical conditions. The Company offers customized assay development and manufacturing services for POC tests and digital reader platforms. It also directly develops, manufactures, and commercializes, Lumos-branded POC tests that target infectious and inflammatory diseases. The Company's products include FEBRIDX, COVIDX, and ViraDx. FebriDx is a point-of-care test which can be used to detect and aid in differentiating bacterial from viral acute respiratory infections. ViraDx is a point-of-care, three-in-one COVID-19/Flu A/Flu B rapid antigen test. Its services include assay development, reader development, cloud and data, and manufacturing. It manages the full development program for point-of-care (POC) assays, from sourcing and/or generation of reagents, right through to verification and validation.
More about the company

Quarterly revenue - Rate of surprise